Last reviewed · How we verify
Aripiprazole + desvenlafaxine succinate sustained release
Aripiprazole acts as a dopamine D2/D3 receptor partial agonist while desvenlafaxine inhibits serotonin and norepinephrine reuptake, together addressing both psychotic and depressive symptoms.
Aripiprazole acts as a dopamine D2/D3 receptor partial agonist while desvenlafaxine inhibits serotonin and norepinephrine reuptake, together addressing both psychotic and depressive symptoms. Used for Adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant monotherapy.
At a glance
| Generic name | Aripiprazole + desvenlafaxine succinate sustained release |
|---|---|
| Sponsor | Pfizer |
| Drug class | Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination |
| Target | Dopamine D2/D3 receptors (aripiprazole); serotonin transporter (SERT) and norepinephrine transporter (NET) (desvenlafaxine) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Aripiprazole stabilizes dopamine neurotransmission by functioning as a partial agonist at D2 and D3 receptors, reducing excessive dopaminergic activity in psychosis while maintaining baseline tone. Desvenlafaxine, an active metabolite of venlafaxine, increases synaptic serotonin and norepinephrine by inhibiting their reuptake transporters, addressing mood and anxiety symptoms. This combination targets both the positive symptoms of psychosis and comorbid depression or anxiety.
Approved indications
- Adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant monotherapy
Common side effects
- Akathisia
- Tremor
- Headache
- Nausea
- Insomnia
- Weight gain
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: